Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
Portfolio Pulse from Benzinga Newsdesk
Can-Fite BioPharma Ltd. (NYSE:CANF) has submitted a pediatric study plan to the U.S. Food and Drug Administration (FDA) for the treatment of adolescents suffering from psoriasis with Piclidenoson. This is a part of the company's ongoing efforts to advance a pipeline of proprietary small molecule drugs that address oncology, inflammatory, and liver diseases.
August 18, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Can-Fite's submission of a pediatric study plan to the FDA for Piclidenoson's use in treating adolescent psoriasis could potentially open a new market segment for the company. However, the outcome depends on FDA approval.
The submission of a pediatric study plan to the FDA is a significant step for Can-Fite as it could potentially open a new market segment for the company. However, the impact on the company's stock will depend on whether the FDA approves the plan. Until then, the news is likely to have a neutral impact on the stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100